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Abstract
The nucleus of the cell serves to maintain, regulate, and replicate the critical genetic information
encoded by the genome. Genomic DNA is highly associated with proteins that enable simple
nuclear structures such as nucleosomes to form higher-order organisation such as chromatin
fibres. The temporal association of regulatory proteins with DNA creates a dynamic environment
capable of quickly responding to cellular requirements and distress. The response is often mediated
through alterations in the chromatin structure, resulting in changed accessibility of specific DNA
sequences that are then recognized by specific proteins. Anti-cancer drugs that target cellular DNA
have been used clinically for over four decades, but it is only recently that nuclease specific drugs
have been developed to not only target the DNA but also other components of the nuclear
structure and its regulation. In this review, we discuss some of the new drugs aimed at primary
DNA sequences, DNA secondary structures, and associated proteins, keeping in mind that these
agents are not only important from a clinical perspective but also as tools for understanding the
nuclear environment in normal and cancer cells.
Introduction
Numerous alterations in the nuclear environment occur
in the development of cancer. In the past several decades,
a major focus of cancer research has been discovering and
understanding these tumourigenic events. These include
small-scale changes in DNA sequences such as point
mutations; larger scale chromosomal aberrations such as
translocations, deletions, and amplifications; and other
changes affecting chromatin structure including aberrant
DNA methylation and histone modification. In all cases,
these alterations can have dramatic direct effects on gen-
eral nuclear activities, including DNA replication and
repair, or on more specific activities such as the expression
of key growth regulatory genes.
Coincident with understanding tumourigenesis has been
the development of agents to treat patients with cancer.
The current focus in anti-cancer drug design attempts to
mimic the uniqueness of the cancer with appropriate ther-
apy, in the expectation that treatment regimes will
become increasingly specific for the cancer type and less
deleterious to the overall health of the patient.
The goal of this review is to discuss some of the current
strategies that specifically exploit our increasing knowl-
edge of the nuclear environment in cancer cells to target
specific cell classes for death. Anticancer drugs that target
DNA have been used in the clinic, with varying degrees of
success, for more than 40 years[1]. These compounds vary
in the type of chemical interaction with DNA, the degree
of sequence selectivity, the extent of lesion reversibility
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and/or ability to be repaired, and cancer cell susceptibility
to their action. Classical DNA binding drugs have been
considered as non-specific cytotoxic agents, with most of
their therapeutic effects due to cytokinetic differences
between normal and cancer cells. More recently, DNA
interacting agents are being designed to affect specific
nuclear functions, through interaction at designated pri-
mary DNA sequences, genomic locations, DNA secondary
structures, or DNA-associated proteins[1].
Levels of structural organisation of DNA
The effects of DNA interacting drugs within cells can be
experimentally observed at many different levels (Figure
1). The first, most basic level, is the chemical interaction
of the drug with the DNA double helix. A variety of tech-
niques have been developed to examine this level of inter-
action, and have shown that the chemistry of the
interaction is very similar if studied on naked DNA or in
cells in culture. Alkylation at specific sites and sequences
in cells can be examined by using a modified thermal
cleavage assay[2]. Following reaction of cells with the
DNA alkylator, genomic DNA is extracted and heated to
induce breaks at alkylation sites. The frequency of breaks
can be ascertained by measuring the presence of modified
nucleotide residues using HPLC or mass spectrometry.
Time course experimentation can be performed to deter-
mine how the DNA adduct is maintained in the context of
the nuclear environment. The site of alkylation and pre-
ferred sequence can be examined in cells using PCR stop
assays wherein the DNA adduct prevents Taq polymerase
elongation, or by ligation of the broken DNA with linker
DNA molecules, followed by site-specific PCR and analy-
sis of recovered products [3-7]. Compounds that bind
tightly but reversibly to DNA can be analysed for their
binding sites by footprinting assays, where short, defined
DNA sequences (100–400 bp) are treated with random
DNA-breaking agents in the presence of the compound,
which protects from cleavage at its preferred binding
sequences. This technique has been extensively used to
study minor groove binding drugs such as distamycin A
and the bis(benzimidazole) Hoechst 33258 [8-12].
A second degree of interaction is the disruption of DNA/
protein or other nucleic acid interactions (such as impor-
tant DNA secondary structures) that result from the drug/
DNA interaction. Transcription factors, chromatin-associ-
ated proteins, and proteins involved in replication,
recombination and repair are examples of proteins that
recognize aspects of the DNA double helix (major versus
minor groove, B versus non-B form DNA), certain DNA
sequences and regions, or other DNA modifications, all of
which could be affected by drug binding. The drug/DNA
interaction might stabilize a transient DNA structure,
introduce a new conformation or structure, or mask a
DNA modification and in these ways alter the normal reg-
ulatory processes working at these sites [13-15]. Some of
the proteins that have been examined include the high
mobility group (HMG) proteins [16-20]. These chroma-
tin-associated proteins induce DNA bending, recognize
distorted DNA structures, and play a role in regulating
gene expression, repair and recombination. Electromobil-
ity shift assays (EMSA) [21-25] and chromatin immuno-
precipitation (ChIP) [26-30] are some of the methods
used to assess DNA/protein interactions in vitro and in
vivo. Expression microarrays and real-time reverse tran-
scriptase PCR can be used to assess changes in transcrip-
tion of genes in the presence of DNA-binding
compounds, a likely end product of alterations in protein/
DNA binding. Indeed, transcription of 21 genes with pro-
moters containing match sites for the minor groove-bind-
ing hairpin polyamide/chlorambucil conjugates were
significantly inhibited in the presence of these
compounds[7].
DNA secondary structures, such as those that form during
DNA recombination, or G-quadruplexes found at the
ends of chromosomes and sometimes present within reg-
ulatory regions of genes, are other examples of possible
targets for drug design. Several recent reviews have dis-
cussed some of these structures and their relevance for tar-
geting[13,31,32]. Techniques that are used to investigate
these DNA structures, their orientation and polarity, and
stability in vitro include CD, IR, and NMR spectroscopy, X-
ray crystallography, and molecular techniques such as
native gel electrophoresis, chemical probing of isolated
DNA species with nucleotide-specific cleavage reagents,
PCR and primer extension reaction stop assays [33-37].
More global changes in the nuclear environment can be
visualized using a combination of fluorescence in situ
hybridization (FISH) and confocal microscopy tech-
niques,"ImmunoFISH", a relatively new technology that
allows coincident visualization of protein complexes and
DNA in intact nuclei[38,39]. This type of microscopy ena-
bles visualization of nuclear complexes composed of
DNA and protein, such as nuclear factories[40], the
nuclear matrix attachment sites and organizational cen-
tres for processes of DNA replication and transcription.
Alterations in these complexes that result from drug treat-
ment might not be detected using other molecular tech-
niques. This technology is particularly useful for
examining the nuclear distribution of specific genomic
locations or sequences which might change during the
course of the cell cycle. For instance, this technique has
recently been used to examine distribution and binding of
membrane Tel binding protein (MTBP/TRF2) to telom-
eres during spermatogenesis and the cell cycle[41].
Deconvolution microscopy using fluorescently-labelled
polyamide compounds has also been used to monitor
drug uptake and cellular distribution [7]. TheseCell & Chromosome 2004, 3 http://www.cellandchromosome.com/content/3/1/2
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Levels of Drug/DNA Interactions Figure 1
Levels of Drug/DNA Interactions: A) The first level of interaction is the direct drug interaction with the DNA. Drug bind-
ing frequency and sequence preferences are two examples of evaluations of this level. B) The second level involves the disrup-
tion of DNA interactions with other molecules that result from the drug/DNA interaction such as DNA/protein interactions. 
Another possibility (not shown) is the alteration or stabilization of DNA secondary structures. C) The third level is the 
changes in nuclear activities such as transcription, replication, and repair or disruption in complex ternary structures. Green 
circles, drug/DNA adduct; black lines, DNA strands, chromosome (with loops); yellow oval, red oval, and pink circle, DNA 
associated proteins; blue square, protein modification such as phosphorylation or methylation.
A.  Direct DNA Interaction.  
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technologies will undoubtedly provide insight into the
global effects of drug treatments and aid in future drug
design.
Primary base sequence
The DNA primary base sequence is the simplest level of
complexity governing the genetic code. However, its
importance in regulating nuclear processes should not be
underestimated, despite the inability to always predict
outcomes based on observed patterns. For example, the
consensus sequence for a given transcription factor in a
promoter region does not necessary mean that protein is
constitutively bound to that site. It is because of this
unpredictability that the more complex nature of genomic
DNA is considered in later sections of this review.
We have divided the discussion of DNA primary base
sequence into four sections in order to introduce the types
of anticancer drugs that interact with DNA. These include
non-specific interactions and sequence-specific interac-
tions with repetitive DNA, AT-rich DNA, or stringent con-
sensus binding sites. The structures of the compounds
vary as well as the way in which they interact with DNA. It
is important to realize, however, that clear distinctions
between these groups do not always exist.
Non-sequence-specific (global) DNA damage
One of the key observable differences between many types
of cancer cells and normal tissues is that the former divide
more rapidly. Treating cells with DNA damaging agents
should perturb the cancer cell's ability to divide. The way
in which this is achieved is determined by the type of DNA
lesion, as well as the genetic makeup of the cell. From the
point of view of cancer treatment the desired pathway is
induction of cell death, as DNA repair can lead to the gen-
eration of mutations if the repair is not accurate. If a DNA
lesion is not repaired prior to approach of a replication
fork either by transcription coupled repair or global repair
pathways, the replication fork will stall. A variety of sig-
nals are then sent out by the stalled fork so that the lesion
is either repaired or bypassed, initiation of other replica-
tion origins is inhibited, and possibly apoptosis is
induced [42-44].
Inducing apoptosis in anti-cancer therapy is not as
straightforward as one would expect. The two major apop-
totic pathways are the external death-receptor-induced
pathway (which involves ligands and receptors, for exam-
ple, FAS and TNF) and the mitochondria-apoptosome-
mediated pathway, which is intrinsic and induced by
insults such as chemotherapy and radiation [45]. Intrinsic
programmed cell death is dependent on the activation of
cellular checkpoint proteins. In the case of DNA damage,
sensing proteins, such as RAD9, RAD1, RAD17, and
HUS1, relay the damage signal to signal transducers
(Mek1, ChK1, Rad53 in yeast; ATM, ATR, ChK1, and
ChK2 in mammals) and effectors (p53, BRCA1, repair
proteins, etc) [46]. In mammals the story is not as clear as
it is in yeast, although many mammalian homologues of
the yeast proteins have been identified. Other protein
complexes may play roles in damage sensing such as the
BRCA1-associated genome surveillance complex which
includes BRCA1, ATM, the MRE11-RAD50-NBS1 (MRN)
complex, MSH2/6 and MLH2 mismatch repair proteins,
and Bloom's helicase[47]. Activation of the damage
response pathway can lead to arrest of cells at various
stages in the cell cycle, induction of DNA repair, and acti-
vation of specific gene expression, as well as apoptosis.
P53 is an important G1 checkpoint protein that prevents
passage of the cells into S-phase via transactivation of the
cyclin-dependent kinase (CDK) inhibitor, p21waf1/cip1
[48,49] but also plays a role in other cell cycle check-
points. Other examples of proteins involved in the G1/S
checkpoint include Rb-E2F pathway, G1 cyclins, and the
ARF proteins[46,48,49].
The S-phase checkpoint involves ATM, ATR, ChK1 and
ChK2 proteins [50-54] and leads to inhibition of initia-
tion of replication at origins and stalling of replication
forks. How this checkpoint manifests in upper eukaryotes
is not entirely clear although in yeast, when a lesion is
encountered by a progressing replication fork, replication
protein A (RPA) binds to the single stranded DNA about
the lesion which in turn recruits the Mec1/Dcd2 sensing
complex (Mec1 is a homolog of mammalian ATR and
ATM). This sensing complex associates with Rad24/Rfc2-
5, and Rad53 (Rad53 is the ChK2 homolog) is then
recruited and activated by phosphorylation in a Mec1
dependent manner [42,55]. In mammals, the DNA dam-
age signal is sensed by ATM and ATR proteins and propa-
gated directly or via the ChK1 and ChK2 kinases to
downstream effectors including p53, BRCA1, Mus81 and
CDC 25 [52]. It should be noted that the exact roles these
damage response proteins play in yeast and mammalian
cells is not necessarily the same. ATM has also been shown
to phosphorylate the Nijmegen breakage syndrome gene
(NBS-1)  in vitro and  in vivo in mammalian cells in
response to γ-irradiation [56]. NBS-1 is a component of
the MRN complex which is involved in recombination
and repair, and thus provides a direct link between the
checkpoint proteins and DNA repair[53]. BRCA1 has also
been shown to be phosphorylated in an ATM-dependent
manner following DNA damage and to bind to the MRN
complex [57-59].
Induction of apoptosis involves activation of signalling
pathways that often shift the balance from anti-apoptotic
proteins to pro-apoptotic proteins, leading to cell cycle
arrest and activation of caspase enzymes. The apoptotic
cell is characterized by loss in cell volume, membraneCell & Chromosome 2004, 3 http://www.cellandchromosome.com/content/3/1/2
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blebbing, nuclear condensation, chromatin aggregation
and endonucleolytic DNA fragmentation [45]. A variety of
techniques can be used to analyze apoptosis, including
flow cytometry (annexin V labelling of externalized phos-
phatidylserine, caspase activation using fluorescently
labelled caspase inhibitors, and PI-staining DNA content
analysis), microscopy (morphological changes) and gel
electrophoresis (DNA laddering). In most cases more than
one method is employed to clearly define the apoptotic
process. This is particularly important when studying
induction of apoptosis in cancer cells compared to nor-
mal cells, because expression of growth factors, tumour
suppressor proteins and other cell cycle inhibitors is
deregulated leading to unexpected outcomes in these clas-
sical apoptosis assays. In addition, different cell types may
not activate all the pathways that result in the apoptotic
cell phenotype.
The first drugs to be used to treat highly proliferative can-
cers were the relatively non-specific nitrogen mustard
DNA alkylating agents[1] such as chlorambucil [1], mel-
phalan [2], and cyclophosphamide [3]. These form
monoadducts primarily at any G-N7 site in the major
groove. However, the biologically important initial lesion
formed by mustards in cells is interstrand cross-links, pri-
marily at 5'GPuC sequences[60]. There is also evidence
that they cause termination of transcription [61]. Cyclo-
phosphamide is the most widely used mustard clinically,
and is a non-specific prodrug of the active metabolite
phosphoramide mustard, requiring enzymic activation by
cellular mixed function oxidases. The (necessarily) high
chemical reactivity of mustards leads to rapid loss of drug
by interaction with other cellular nucleophiles, particu-
larly proteins and low molecular weight thiols. This
results in the development of cellular resistance by
increases in the levels of low molecular weight thiols (par-
ticularly glutathione) [62,63]. Of equal importance for
efficacy, much of the drug can reach the DNA with only
one alkylating moiety intact, leading to mono-alkylation
events which are considered to be genotoxic rather than
cytotoxic[64]. The fact that cross-linking is a two-step
process adds to the proportion of (genotoxic)
monoalkylation events, since the second step is very
dependent on spatial availability of a second nucleophilic
DNA site. Because of their genotoxicity, there is a risk of
the development of second cancers from their mutagenic
effects, with the most frequent alkylator-induced malig-
nancy being acute leukemia[65], usually occurring a long
period (3–7 years) after treatment.
Another class of even less selective alkylating agents is
those which break down to very unstable intermediates
that react indiscriminately. These include nitrosoureas
such as streptozotocin [4], which has been used as a com-
ponent of multi-drug protocols for Hodgkin's disease
[66], and triazenes such as dacarbazine [5], widely used
for malignant melanoma[67], and the more recent temo-
zolomide [6], used increasingly for gliomas [68].
Mitomycin C [7] is an example of a more complex and
sequence-specific DNA cross-linking agent. It is widely
used clinically, perhaps most effectively now in bladder
cancer [69], but its use is limited by myelosuppressive
side-effects. The mitomycin C-related FR family of antibi-
otics, including FR900482 [8] and related compounds,
are compelling potential replacements which may in
some cases offer decreased toxicity[26,27]. The FR family
of compounds undergo reductive activation to form reac-
tive mitosene derivatives, which crosslink DNA preferen-
tially at 5'CpG'3 steps[26]. Although generally considered
a non-selective agent, there is some evidence that mitomy-
cin and related compounds have shown some selective
effects in cells. Using a modified ChIP assay with Jurkat T
cells, FR900482 was shown to crosslink regions in the IL-
2 and IL-2Rα promoters and the HMG I/Y, HMG 1, and
HMG 2 minor groove binding proteins and not the major
groove binding proteins (with overlapping DNA target
sequences), Elf-1 and NFκB[26].
Repetitive DNA sequences
We now know that the human genome contains consider-
able areas of repetitive DNA sequences [70,71]. These are
generally organized in heterochromatin, mainly in centro-
meres. These satellites consist of repeat units of several
thousand base pairs. Minisatellites (also called variable
number tandem repeats) and microsatellites (also called
short tandem repeats) are distinctly different from
satellites in that the repeat units are shorter and less com-
plex, and they are dispersed across the genome. The differ-
ence between minisatellites and microsatellites is the
latter repeat length is between 1 and 13 bp whereas the
minisatellite is longer. In some cases mini- and microsat-
ellites may serve important regulatory functions. For
instance, a vast majority of the CGG trinucleotide repeats
are located in the 5' untranslated regions of genes and are
oriented with respect to the transcribed strand such that
the mRNA contains the repeat. In addition, repetitive
DNA often has the ability to take on non-B form DNA
conformations which might recruit certain regulatory pro-
teins that participate in control of gene expression.
"AT-islands", containing between 85–100% AT, are dis-
tinct minisatellite regions[3-6,15]. These islands consist of
between 200 to 1000 bp of repetitive DNA. A number of
critical nuclear processes are organized around AT-rich
DNA sequences in the genome. In some instances, these
islands function as matrix attachment regions (MARs)
that organise DNA loops on the nuclear matrix and coor-
dinate nuclear activities such as DNA replication, tran-
scription, and mitosis[15]. Nuclear matrix binding abilityCell & Chromosome 2004, 3 http://www.cellandchromosome.com/content/3/1/2
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of DNA sequences can be demonstrated in vitro by prepar-
ing nuclear matrices and incubating with labelled DNA
probes of sequences of interest and unlabeled competitor
DNAs (either non-specific or MAR containing), followed
by gel electrophoresis of washed matrices. In vivo MAR
binding activity can be assessed by digestion of nuclear
DNA with a number of enzymes that do not cleave within
the potential MAR, followed by nuclear matrix prepara-
tion to separate the matrix-associated DNA from loop
DNA. Labelled probes are then used to screen dot blots of
prepared matrices and associated DNA. Enrichment of
DNA sequences within the nuclear-matrix fractions versus
loop DNA fraction is highly suggestive of MAR
activity[72].
Repetitive sequences, like these "AT-islands", are notori-
ously unstable elements with changes occurring either
through polymerase slippage or unequal recombina-
tion[71]. The types of rearrangements that often occur at
these sites include expansion and deletion of the repeti-
tive elements. Not surprisingly, mini- and microsatellite
instability features in a number of human diseases and
cancers, such as human colorectal cancer and a variety of
leukaemias and lymphomas. Using a variety of experi-
ments including in vitro and in vivo MAR binding assays,
Jackson et al[72] have recently demonstrated that the AT-
islands within the FRA16B fragile site are expanded and
preferentially associated with the nuclear matrix in the
CEM leukaemia T cell line as compared to normal WI-38
fibroblasts. This alteration in the organization of DNA in
the leukaemia cell line correlates with a hypersensitivity to
drugs which specifically alkylate in repetitive AT-rich
regions [4,6,15].
Origins of replication and various promoter sequences are
other examples of AT-rich sequences. Unlike simpler
eukaryotes, mammalian origins of replication are not as
clearly defined or localized on individual chromosomes.
Sites have been identified however, such as the c-MYC ori-
gin that lies in the 5' region of the gene. This site is AT-rich
although the c-MYC MAR located in the 3' region of the
gene has a significantly higher AT content. Destabilization
of these regions would undoubtedly affect the cell's ability
to initiate DNA synthesis, although the impact this would
have on cellular proliferation is not necessarily predicta-
ble. Genetic changes associated with instability could also
affect gene expression.
Many genes have been identified that contain mini- and
microsatellites of all sorts, expansions or other alterations
of which have been implicated in deregulation and asso-
ciation with disease[70,71]. Examples include the CAG
repeat in the Huntington's gene, the G/C rich repeat 600
bp upstream of the insulin gene ATG (insulin-dependent
diabetes mellitus), the GAA repeat in the X25 intron asso-
ciated with Friedreich's ataxia, and the G/C rich repeat
downstream of the HrasI polyA signal, certain alleles of
which are associated with increased cancer risk.
AT-rich regions (ORIs, MARs)
The metabolic processes at AT-rich minisatellites may be
directly affected by drug-induced DNA lesions and/or hin-
dered by the induction of cellular checkpoints and DNA
damage response pathways. For example, drugs that inter-
act specifically at such sites could interfere with essential
protein/DNA interactions that then lead to delay in or
inhibition of DNA synthesis or deregulation of gene
expression. Drug interference could result from competi-
tion for factor binding to the sequence, deletion or altera-
tion in the DNA sequence as a result of repair processes,
and/or distortion in the local DNA confirmation[14,15].
The cyclopropyindoline compounds, including the natu-
ral product CC-1065[73,9] and related synthetic ana-
logues like adozelesin [10] and bizelesin [11], are
extremely cytotoxic DNA alkylators that target the N-3 of
adenine in the minor groove of AT-rich DNA sequences.
Even simpler analogues such as the hydroxyl- and ami-
noCBI compounds [12] and [13] show very similar pat-
terns of DNA alkylation when compared on a section of
the  gpt  gene, alkylating preferentially at 5'-A(A/T)AN
sequences, although the amino analogue was the more
efficient alkylator[2], and showed similar levels of
potency in a variety of cell lines[74]. A comparison of the
monoalkylating derivative, adozelesin, and the related
bifunctional analogue, bizelesin, showed that while both
are highly AT-selective, the latter requires a target site with
adenines spaced six base pairs apart, and most commonly
alkylates by crosslinking adenines very preferentially at
T(A/T)4A sites[75]. Monoadducts have also been observed
at A(A/T)4A sites, although to a lesser extent [3,4,76]. In
silico drug/DNA binding analysis predicts that the bize-
lesin binding motif occurs approximately 2.8 times every
250 bp. AT-island hotspots are present once every 106 bp,
and within these hotspots bizelesin sites occur 99 times
every 250 bp. These long AT-islands are suspected to be
the major targets for bizelesin binding and responsible for
its high toxicity. Using a model AT-island DNA, actual
bizelesin binding sites were determined and confirmed
the in silico predictions. Bizelesin was 100 times more
reactive with the model AT-island DNA than the non-AT-
island model[6,15].
Woynarowski in a recent review[15] has suggested that the
potent cytotoxicity of the general indoline class of toxins
is caused by disruption in critical nuclear processes that
are organized around functional AT-rich DNA sequences
in the genome. Matrix attachment regions, origins of rep-
lication, and candidate promoters are examples of AT-rich
sequences that might be specifically targeted by theseCell & Chromosome 2004, 3 http://www.cellandchromosome.com/content/3/1/2
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compounds as a result of their alkylation preference and
sequence specificity. Furthermore, hits to AT-rich
sequences by the region-specific AT binding drugs such as
bizelesin or other AT-specific drugs like tallimustine that
are not organized in these regions would be much less del-
eterious to the cell because of a lack of functional conse-
quence. The variation in cytotoxic potencies of different
indoline analogues and other AT-specific drugs could
result from the ability to target these regions effectively.
The degree of susceptibility of a cancer cell to these agents
may depend on a number of additional factors including
deregulated gene expression and genomic instability, and
in this way these compounds may be more specifically
toxic to cancer cells. Woynarowski and co-workers[6] have
found that the AT-rich fragile sites Fra16B and Fra16D,
and the c-MYC origin, a region commonly amplified in
cancer cells, are targeted by bizelesin. In addition, we have
found that 50% of the recovered mutations in the gpt gene
of surviving AS52 Chinese hamster ovary cells treated with
aminoCBIs are deletions in AT-rich regions (unpub-
lished). Thus, specifically localized DNA damage can
result from treatment with drugs of this class and may
contribute to the potent cytotoxicity[15]. Given the
increased level of genomic instability in cancer cells, drug
potency may be enhanced due to expansion of these satel-
lite regions and/or because of deletions in these critical
regions following drug treatment.
CC-1065, bizelesin and adozelesin have been shown to
inhibit DNA replication in cell-free and cell-based systems
(yeast and mammalian) [77-82]; however, the mecha-
nism of inhibition is not clearly understood. Based on the
DNA/adduct distortion studies[83,84], replication initia-
tion may be inhibited by distortion of specifically targeted
MARs resulting in a block in origin complex assembly nec-
essary for proper origin firing. This could explain the very
high lethality of bizelesin (<10 adducts per cell leads to
inhibition of growth) compared to that for the AT-specific
alkylator tallimustine [14] (>200 per cell) and conven-
tional mustards (several thousands per cell)[15] which do
not demonstrate region-specific DNA binding.
Another reason why selective damage to AT-rich DNA
might be important in the mechanism of drug action is
that binding to these sequences affects specific gene
expression. This may arise by preventing transcription fac-
tor binding, increasing the affinity of a transcription factor
for its sequence, or creating unnatural binding sites. For
example, CC-1065 has been shown by EMSA to inhibit
TATA Box Binding protein (TBP) from binding to a DNA
oligonucleotide containing the adenovirus major late pro-
moter TATA box sequence[21]. In this case, drug binding
was thought to directly hinder minor groove binding of
TBP to the TATA box. Binding of Specificity Protein 1
(SP1), a member of the SP/KLF family of transcription fac-
tors[85], to 6 GC boxes present in the simian virus 40
(SV40) early promoter is also inhibited by CC-1065 bind-
ing to AGTTA* between the SP1 sites, where * indicates
the site of covalent modification[83]. These authors pro-
pose that the inhibition in SP1 binding, particularly at the
3'-GC box, resulted from distortions in the DNA caused
by adduct formation. High-field NMR studies of the
adozelesin/DNA adduct have confirmed that drug bind-
ing distorts the DNA double-helix despite maintaining
normal Watson-Crick base pairing[84]. AT-rich sequences
found in regulatory regions in other genes associated with
cancer, such as c-MYC, have also been identified as sites
specifically alkylated in cells treated with related com-
pounds[4]. Using a similar approach (real-time PCR stop
assay) we have found that the aminoCBI compounds also
target AT-rich sites located within the c-MYC gene in cell
culture, and furthermore using real-time reverse tran-
scriptase PCR analysis, we have found that c-MYC expres-
sion rapidly (within a few hours) decreases following
treatment (unpublished). We are currently extending
these studies to look at changes in protein expression
levels.
Specific DNA sequences (oncogenes)
Hairpin polyamides
There are several drug classes that are able to span DNA
and recognise a limited number of specific sequences. The
most discriminatory sequence selective DNA binding
compounds to be developed are the pyrrole-imidazole
(Py-Im) polyamides[10,86,87]. These minor groove
binding compounds are synthetic ligands that were devel-
oped based on the binding properties of the AT base selec-
tive drug distamycin A [15,88]. The dimeric hairpin Py-Im
polyamides derivatives have been shown to inhibit tran-
scription factor binding, such as TBP, NFκB, and ETS-1, to
recognition sequences in vitro [89-91]. Another recent
study demonstrated that Py-Im polyamides can derepress
expression of the HIV long terminal repeat by inhibiting
host factor LSF binding to the repressor complex sequence
in the context of host cell chromatin [92]. Despite success-
ful inhibition of transcription factor binding to naked
DNA, the hairpin polyamides have not proved to be effec-
tive at inhibiting gene expression in cells[7].
A new approach is to conjugate polyamides with DNA
alkylating agents such as chlorambucil (Py-Im-Chl) [16],
in the expectation of increasing their biological potential
and hence therapeutic use [91,93,94]. These derivatives
were shown to inhibit in vitro replication of SV40, mam-
malian cell growth, and genomic DNA replication, and
cells treated with Py-Im-Chl conjugate arrested in G2/
M[93]. More detailed analysis of the accessibility of
nuclear chromatin and effects on gene expression have
been performed using the Py-Im-Chl conjugate byCell & Chromosome 2004, 3 http://www.cellandchromosome.com/content/3/1/2
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Dudouet et al.[7]. Using ligation-mediated PCR to exam-
ine alkylation sites, these investigators found that the Py-
Im-Chl conjugate was capable of accessing target binding
sites in the HIV-1 enhancer and promoter in lymphoid
cells. Microarray analysis of cellular expression profiles
indicated that a limited number of genes (21 genes using
2 conjugates) were affected by polyamide-conjugate treat-
ment, and that in each case match sites were located
within the 5'-flanking region of the gene. While it is still
not known how effective these agents will be clinically, it
is very promising that the expression of so few genes can
be altered considering the number of potential polyamide
binding sites for these agents within the entire human
genome (experimentally determined to be approximately
1 in 1900 bp, expected frequency calculated to be present
1 in 2048 bp)[7].
Ecteinascidin (Et-743)
Et-743 [17] is a minor groove alkylating agent which was
originally isolated from the sea squirt Ecteinascidia turbi-
nata, and is currently in clinical development [95,96].
Alkylation by Et-743 of the N2 of the central guanine of
the DNA binding triplet results in a conformational
change in the DNA, with the minor groove widening and
the double helix bending towards the major groove [97-
101]. Et-743 does not have the same degree of DNA
sequence specificity as the polyamide compounds. How-
ever, this compound does demonstrate a unique potential
to alter gene expression of discrete loci based on the pres-
ence of GC boxes in the promoter regions. The potent
cytotoxicity of Et-743 is thought to be due to inhibition of
transcription factor binding, resulting in effects on tran-
scription. For example, DNA binding of NF-Y to the
CCAAT box and the transcriptional activation of MDR1
and HSP70 (genes regulated in part by NF-Y via the
CCAAT motif) are affected by Et-743 [102-104]. Interest-
ingly, constitutive expression of MDR1 and HSP70 is not
affected[103]; therefore, Et-743 may work via inhibiting
activated transcription in response to certain stimuli[105].
Microarray analysis of tumour cell lines treated with Et-
743 and phthalascidin [18] (Pt 650)[106], a synthetic
analog of Et-743, showed similar changes in gene expres-
sion including a decrease in expression of genes which
bind to CCAAT-boxes which might contribute to the
repression in activation of transcription of MDR1  and
HSP70 [105,107].
Et-743 also inhibits the transcription of other genes,
including c-FOS, c-JUN, E2F1, H2B, and H4. The mecha-
nism is presumably by alkylation of the guanine bases in
the GC boxes present in the promoter regions, resulting in
a block in the binding of transcription factors such as NF-
Y, SP1 and ERG1[108].In vitro inhibition of the transcrip-
tion factors TBP, E2F, and SRF has also been
observed[102]. Modelling studies suggest that head to tail
binding of three Et-743 molecules to DNA resembles an
RNA-DNA hybrid complex, and that the distortions men-
tioned above mimic those induced by zinc finger tran-
scription factor binding[109]. These investigators have
speculated that such changes in the DNA could not only
inhibit factor recognition but also induce DNA/Et-743/
protein interactions. Et-743 also seems to exert its cyto-
toxic effect on cells by inducing single-strand DNA breaks
(ssDB) via an interaction with the transcription-coupled
repair machinery, as cells resistant to Et-743 have defects
in the xeroderma pigmentosum genes, and show reduced
ssDBs following treatment[110,111]. Mutations in the
DNA double-strand break repair pathway, however, sensi-
tize cells to Et-743 cytotoxicity[110]. Taken together, these
studies suggest that while inhibition of transcription fac-
tor binding to certain promoters is an important part of
the Et-743 mode of action, the anti-tumour activity is also
dependent on endogenous features of the cancerous cell
such as certain DNA repair pathways.
Secondary DNA structures
In the previous section of this review we discussed the bio-
logical impact of several different DNA-interacting com-
pounds including the nature of their interaction with
DNA, mechanism of action, and known anti-cancer activ-
ity. In addition to small molecules that interact with spe-
cific bases and base sequences, a number of compounds
are being developed which target DNA secondary struc-
tures such as DNA tetraplexes and quadruplexes, hairpins,
and Holliday junctions. Some of these DNA structures
have been implicated in regulating numerous nuclear
activities, and represent an exciting new area of research
into potential anti-cancer targets as well as for treatment
of numerous other human diseases including diabetes
and neurodegenerative disorders[112].
DNA quadruplexes (telomeres)
Telomeres are the repetitive DNA sequences (TTAGGG) at
the ends of chromosomes that protect the 3' ends from
degradation and inappropriate repair activities and inter-
act with a number of different proteins forming the telo-
meric complex [113-115]. In normal proliferating cells,
telomeres are shortened with each round of replication
and telomerase expression is negligible. Eventually, tel-
omeres become so short that they are no longer capable of
protecting chromosome ends, leading to chromosome
fusions and erosion. This results in the induction of "tel-
omere-induced senescence" and loss of cell viability. In
many cancer cells, however, a short telomere length is
maintained during cell divisions in part because of
increased telomerase activity. In fact more than 90% of all
human cancers have increased expression of telomerase
which is one reason why it has been suggested as a target
for anti-cancer drug design efforts. In addition to the tel-
omerase enzyme, the telomeric DNA structure is beingCell & Chromosome 2004, 3 http://www.cellandchromosome.com/content/3/1/2
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examined for its ability to be targeted by anti-cancer
treatments[114,116-121].
Telomerase is a multi-component enzyme comprised of
protein and nucleic acid. The two main components are
the RNA moiety (hTER) and the catalytic subunit
(hTERT), although there are several additional regulatory
binding proteins (for example: HSP90, p23, and TEP1).
There are numerous telomerase inhibitors in develop-
ment[120]. The main strategies include anti-sense oligo-
nucleotides, peptide nucleic acids and ribozymes
targeting the RNA component of telomerase, dominant
negative versions of the hTERT subunit, small molecule
inhibitors of the enzyme complex, and disruption of the
G-quartet (see below)[120,122,123]. While decreases in
telomerase activity have been achieved using these
approaches, this has not necessarily led to reduced cancer
cell viability.
The G-quartets of the telomere (3' G-rich overhang of
150–200 bp that form the DNA secondary structure, the
G-quartet) are stacked tetrads arising from planar associa-
tions of four guanines in a cyclic Hoogsteen hydrogen-
bonding arrangement (Figure 5) [32]. G-quartets can be
stabilized by sodium and potassium ions, and this stabili-
zation can inhibit telomerase activity. As such, the ability
of small molecules to interact with and presumably stabi-
lize these secondary structures as a means of inhibiting tel-
omerase has been a major drug design effort.
A number of small molecules have been identified that
interact with G-quartets. Molecular modelling studies of
anthraquinones predicted these compounds would inter-
act with G-quartets by a threading intercalation model
[124]. Nuclear magnetic resonance studies have con-
firmed that the 2,6-diamidoanthraquinone BSU1051 [19]
interacts with and stabilizes the G-quartet, and inhibits
telomerase activity[125]. A 3,6,9-trisubstituted acridine
[20] was also a potent (IC50 18 nM) inhibitor of telomer-
ase[126]. In A431 human squamous cell carcinoma
xenografts it showed a significant additional growth delay
compared with paclitaxel alone, with no additional
toxicity[127].
Cationic porphyrins, exemplified by TMPyP4 [21], are
another class of agents that were predicted to bind to G-
tetrads by interactive stacking[32]. Two independent
research groups showed by a variety of methods (spectros-
copy, CD, NMR) that these compounds do interact with
parallel and anti-parallel G-quadruplexes[32,128]. The
way in which the compounds interact with the DNA is not
entirely clear, but most likely involves external stacking of
the porphyrins relative to the G-quadruplex[129]. A third
class of G-tetrad interacting compound is typified by the
perylenetetracarboxylic diimide PIPER [22] that demon-
strates similar binding attributes to the porphyrins. Inter-
estingly these compounds may not merely bind to such
DNA structures, but may also induce their formation in
cells [130].
In addition to telomeres, G-quadruplex sequence motifs
have been identified in other regions of the genome, par-
ticularly in the upstream promoter regions of a number of
oncogenes [34]. Within the c-MYC promoter, the nuclease
hypersensitive element III1 (NHE), corresponding to
bases 2186–2212 in human c-MYC  [131], has been
known to play an important role in regulation of c-MYC
expression. Insight into the regulatory nature of this
region was first demonstrated when synthetic oligonucle-
otides with sequences complementary to the NHE c-MYC
coding were capable of blocking c-MYC  expres-
sion[132,133]. Further in vitro studies using c-MYC pro-
moter DNA demonstrated this region was capable of
forming quadruplex structures (G-rich strand) and i-tetra-
plexes (C-rich strand) [34-36]. These latter structures are
formed based on hemiprotonated cytosine+/cytosine base
pairs containing three stabilizing hydrogen bonds
between them. The four-stranded structure is composed
of two parallel-stranded duplexes zipped together in an
anti-parallel configuration [134-136]. In the case of the c-
MYC  promoter the formation of the G-quadruplex
appears to be the biologically relevant structure.
The use of G-quadruplex stabilizing compounds targeted
at telomeres prompted the investigation of affects within
the c-MYC locus. Using the cationic porphyrin, TMPyP4,
Grand  et al. (2002)[137] and Siddiqui-Jain et al.
(2002)[33] have demonstrated repression of transcrip-
tional activation of c-MYC in cells based on G-quadruplex
stabilization. In addition, mutational analysis by replace-
ment of a G to an A within this G-rich region which is pre-
dicted to destabilize quadruplex formation results in a 3-
fold increase in c-MYC expression also points to a biolog-
ical role for this secondary structure [33].
Hairpins and Holliday junctions (mini- & micro-satellites)
A variety of secondary structures (hairpins, cruciforms)
have now been detected in the genomic DNA of a number
of prokaryotic and eukaryotic species, including humans.
These structures are associated with regulation of gene
transcription, possibly as recognition binding sites, and
may be targets for selectively binding drugs that could
either block or enhance transcription[138]. Thus, the
potent transcription inhibitor actinomycin D [23] and
analogues bind at least 10-fold more tightly to the hairpin
conformation formed from the single-stranded DNA 5'-
A7TAGT4A3TAT7-3' than to same strand fully duplexed to
its complementary sequence[139]. Similar results have
been reported for actinomycin D binding to GC-rich hair-
pin sequences [140].Cell & Chromosome 2004, 3 http://www.cellandchromosome.com/content/3/1/2
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DNA Secondary Structures: G-Tetrad and G-quadruplex Figure 5
DNA Secondary Structures: G-Tetrad and G-quadruplex. A) Schematic illustration of G-tetrad, four guanine bases in a 
planar arrangement through Hoogsteen hydrogen bonds; B) G-quadruplex, parallel arrangement of four DNA strands; C) 
Intermolecular G-quadruplex, DNA sequences with G-rich repeats forming hairpins that dimerize to stablize bimolecular 
structure; and D) anti-parrallel intramolecular G-quadruplex (fold-over G-quadruplex), single DNA strand with four G-rich 
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DNA four-way junction structures (Holliday junc-
tions)[141], often created by mismatches, are known to
occur during DNA replication, repair and recombination,
making them potential targets for the development of
novel antiviral and antibacterial agents. Human TOPO IIβ
also binds preferentially to four-way junction DNA[142],
suggesting that it might operate via such structures. It has
long been known that some intercalating agents show
preferential binding to such branched DNA
sequences[143]. Recently, a series of crystal structures of
both mono-intercalators [24-26,144-146] and dimeric
drugs [27,28,144,147], complexed with short oligonucle-
otides, have shown that the ligands can induce Holliday
junction-like DNA structures. It remains unclear whether
this reflects the situation in longer DNA.
Triple helices
DNA duplexes of certain sequences can bind a third DNA
(or modified DNA) strand, to form a triple helix. The third
strand binds to the existing base pairs in a manner called
Hoogsteen base pairing; T binds to A (but in a different
way to normal) and protonated C binds to G, to form the
triplets T.AT and C+.GC[148]. In this way a homopyrimi-
dine third strand can bind to its complementary sequence
of duplex DNA. Triple helices are generally less stable than
the duplexes, and are thought to be induced naturally in
the genome by supercoiling, as triple helix formation can
relieve torsional stress[149]. However, some small mole-
cules can stabilize triple helixes by preferentially binding
to them. Many such compounds, like those that preferen-
tially bind quadruplexes, tend to be intercalating agents of
larger than usual planar area, with side chains in the cor-
rect disposition to bind in one or more of the three
grooves of the triple helix. One of the best-studied is the
benzo [e]pyridoindole BePI [29], that binds T.AT tri-
plets[150]. The related antiviral indoloquinoxaline 9-OH-
B220 [30] provides a very large stabilization of such triplet
species, shifting the triplex-to-duplex equilibrium by up
to 50°C [151]. The other major class of triplex stabilizers
are the aminoglycosides. One of the most effective is neo-
mycin [31], which binds preferentially in the larger
Watson-Hoogsteen groove rather than one of the regular
duplex grooves [152].
DNA-Associated Protiens
Proteins that associate with DNA vary in structure,
sequence and structural binding motifs, degree of interac-
tion, regulation, and role in regulating nuclear metabo-
lism. Protein targets for drug design that will be discussed
in this review include topoisomerase proteins, DNA
methyltransferases, HMGs, TBP and histone deacetylases.
Other transcription factors, repair proteins and other
important nuclear proteins involved in replication and
recombination are also important candidates to consider,
but will not be discussed here.
Topoisomerases
Topoisomerase enzymes are involved in resolving topo-
logical problems in DNA, such as superhelical tension,
that arise during most nuclear activities involving DNA.
Topoisomerase I (TOPO I) acts by introducing one break
in one strand of the DNA, whereas Topoisomerase II
(TOPO II) acts by making a double strand break. Aside
from several intercalating agents such as doxorubicin,
TOPO I and II are the targets of numerous drugs, some of
which function as poisons and others as competitive
inhibitors[153].
The major class of TOPO I poisons is exemplified by
camptothecin (CPT) [32,154], a cytotoxic alkaloid con-
taining an essential six membered lactone ring. This is a
natural product, originally isolated from Camptotheca acu-
minata. It binds to TOPO I[155] in association with DNA
and stabilizes the single-stranded break, preventing strand
passing through the break and subsequent resealing.
Structure-activity studies have lead to the development of
a number of closely related compounds that are also used
clinically. TOPO II poisons can be classified into two
major classes[153]. The DNA intercalators that bind pri-
marily to DNA are exemplified by the anthracycline dox-
orubicin [33], while those that bind primarily to the
protein can be exemplified by the epipodophyllotoxin
etoposide [34]. Both classes of compounds work by for-
mation of a ternary drug/DNA/enzyme complex that
inhibits the DNA resealing activity of the enzyme, stabiliz-
ing the cleavable complex and resulting in DNA double-
strand breaks[156]. Other inhibitors, such as fostriecin
[35] and derivatives, inhibit the catalytic activity of topoi-
somerase without stabilizing the cleavable complex[157].
Changes in the nuclear environment that result from
topoisomerase inhibitors vary. TOPO II is cell-cycle
dependent and expression is higher in actively proliferat-
ing cells leading to their greater susceptibility[158,159].
TOPO II inhibitors generally disrupt the cell-cycle during
S phase because the increased concentration of DNA dou-
ble-strand breaks interferes with DNA replication and trig-
gers apoptosis[153,160]. In the case of CPT, the
generation of DNA breaks in addition to the collision of
the stabilized cleavable complex with the DNA replication
machinery is necessary for cell killing [160-162]. CPT also
blocks the elongation step of transcription[163].
DNA methylases and DNA methylation
Nuclear DNA methylation patterns are often altered in
human malignancies. In some cases, the genome-wide
degree of methylation is reduced and in certain circum-
stances may be responsible for abnormal gene activation.
In other cases, promoters of certain genes are hypermeth-
ylated and this leads to gene silencing [164]. There are at
least three enzymes responsible for DNA methylation ofCell & Chromosome 2004, 3 http://www.cellandchromosome.com/content/3/1/2
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CpG dinucleotides (the transfer of methyl groups from S-
adenosyl-L-methionine to cytosine to form 5-methylcyto-
sine), DNA methyltransferase (DNMT) 1, DNMT3A, and
DNMT 3B. DNMT1 is predominantly responsible for
maintaining methylation patterns during replication,
whereas DNMT3A and 3B are required for de novo methyl-
ation[165].
CpG islands are concentrated regions of CpG dinucle-
otides generally found in promoter regions[166,167].
Methylation of these regions in normal cells generally
occurs on genes located on the inactivated X chromosome
and on selectively silenced alleles[168,169]. In neoplastic
tissue however, methylation can lead to silencing of key
tumour suppressor genes[170]. Tumour suppressor and
growth inhibitory genes, such as p15INK4b, p16INK4a, and
p21WAF1/CIP1, are often silenced in cancer cells by DNA
hypermethylation of their promoter regions[165]. Revers-
ing the degree of DNA methylation using azanucleoside
DNA methyltransferase inhibitors such as 5-azacytidine
[36] and 5-aza-2'-deoxycytidine [37] (decitabine)[171]
reactivates transcription at previously silenced tumour
suppressor promoters[172]. The mechanism by which
these azanucleotides act is via incorporation into the cel-
lular DNA and inhibition of DNMT1 via covalent interac-
tion (thioether bond) at C-6[173] which forces
replication to proceed without DNA methylation. Thus far
these compounds have shown some success in clinical tri-
als [174-177].
Two alternate strategies that have been employed to
inhibit DNMT1 are the use of DNMT1 anti-sense oligonu-
cleotides and the use of hairpin-structured oligonucle-
otide substrate mimics[164]. Fournel et al. [178])
demonstrated that use of antisense oligonucleotides led to
loss of DNMT1 protein, decrease in methylation at the
p16INK4a  promoter, and expression of p16INK4a  RNA.
Although the hairpin mimics effectively inhibit purified
DNMT1 in vitro, they have not been able to induce meth-
ylation changes in cells[179].
Histone acetylation/deacetylation (HDACs)
The regulation of chromatin structure and DNA sequence
accessibility is the subject of extensive research because
they play important roles in governing numerous nuclear
activities including transcription, recombination, and rep-
lication. The basic nuclear DNA unit is the nucleosome; a
146 bp stretch of nuclear DNA wrapped around an
octamer of histone (H) proteins (two each of H2A, H2B,
H3 and H4) [180-182]. Arrays of nucleosomes are then
folded into higher-order structures such as chromatin
fibres. The three known mechanisms influencing chroma-
tin structure are ATP-dependent chromatin remodelling,
histone replacement, and covalent modification of either
DNA or associated histones. In the last case, modifications
include cytosine methylation and histone acetylation,
phosphorylation, methylation, ubiquitination, and ADP-
ribosylation[180]. The regulation of these mechanisms
and their cross-talk in the nucleus affects whether DNA
sequences will be accessible for nuclear processes.
Active transcription is associated with lysine acetylation of
histones and methylation at Lys-9 of H3; whereas, tran-
scriptional repression is associated with deacetylated his-
tones, methylation of Lys-4 of H3 and methylated
DNA[180,181,183,184]. The main mechanism by which
HDACs repress transcription is likely to be the result of
functional linkage between HDACs and DNA methyla-
tion via recruitment of HDAC to DNA by methyl binding
proteins (for example MeCP2 and MBPs1–4)[184]. This
in turn inhibits the recruitment transcriptional activators
such as SWI/SNF, SAGA, and TBP proteins to the pro-
moter regions preventing gene expression[185]. In addi-
tion, the deacetylated histone tails may actively recruit
transcriptional silencers. For example in yeast, Sir3 prefer-
entially binds to non-acetylated DNA and associates with
Sir2/Sir4 to form a "silencing" complex that spreads hete-
rochromatin formation [180,183,186]. Although Sir3 and
Sir4 human homologues have not been identified, the
potential for preferential binding to non-acetylated DNA
is still a feasible mechanism to consider. In addition, it is
important to consider that HDACs may act on other mol-
ecules, such as specific transcription factors and alter their
activation states[180].
There are three major classes of HDACs, although known
inhibitors only work on two of the three classes[187]. The
HDAC I class is composed of proteins that are homolo-
gous to the yeast RPD3 gene; HDAC1,2,3,8, and 11.
HDAC class II is subdivided into two; IIA proteins include
HDAC4,5,7, and 9, IIB proteins are HDAC 6 and 10 and
are characterized by sequence homology to yeast HDAI.
Class III proteins are similar to the yeast repressor protein,
Sir2, although they have not been extensively character-
ized in mammals. The HDAC inhibitors of both HDAC I
and II classes bind and inhibit HDAC activity, induce
acetylation of histones in cells, inhibit tumour cell prolif-
eration  in vitro, and several compounds have shown
promising results in human xenograft experiments [187-
190].
The HDACs are attractive targets for anti-cancer drug
design because they are involved in gene silencing similar
to the DNA methylase targets mentioned above, and a
number of structurally diverse classes of inhibitors are in
development. However, only the first two types of HDACs
are sensitive to the inhibitors developed thus far. These
fall into several structural classes; the short chain fatty
acids, the hydroxamic acids, the cyclic tetrapeptides, the
benzamides, and the epoxides[187].Cell & Chromosome 2004, 3 http://www.cellandchromosome.com/content/3/1/2
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A number of these HDAC inhibitors are at various stages
of clinical study[187]. Phase I studies with suberoylani-
lide hydroxamic acid (SAHA) [38] concluded that it was
well tolerated, inhibited the HDAC activity in vivo (in
peripheral blood mononuclear cells and in post-therapy
tumour biopsy), and has anti-tumour activity in solid
(bladder) and haematological tumours[191]. SAHA is in
phase II development for treatment of cutaneous T cell
lymphoma, peripheral T cell lymphoma, and recurrent or
metastatic squamous cell carcinoma of the head and
neck[187]. The depsipeptide FR901228 (FK228) [39] is in
trials for a variety of leukemias and lymphomas, and
refractory or progressive small cell and non-small cell lung
cancer[192].
The cellular response to HDAC inhibitors is becoming
better characterized. For example, SAHA binds directly to
the HDAC catalytic site, inhibits enzyme activity, inhibits
cellular proliferation and promotes an apoptotic cellular
response [193-195]. Oligonucleotide microarray analysis
of multiple myeloma cells treated with SAHA demon-
strated that commitment to apoptosis is associated with
suppression of genes involved in promoting cell growth
and survival, drug resistance, cell cycle control, DNA rep-
lication and repair, and proteosome function[196].
Combination therapy using HDAC inhibitors and other
agents such as DNA methylase inhibitors and heat shock
protein 90 (HSP90) antagonists have demonstrated a syn-
ergistic effect on cellular responses such as activation of
gene expression and induction of apoptosis [197-202].
For example, using depsipeptide and 5-aza-2'-deoxycyti-
dine treatment of breast cancer cell lines, Primeau et
al.[197] demonstrated synergistic anti-neoplastic activity
and the activation of mapsin and gelsolin gene expression,
two metastatic tumour suppressor genes that are silenced
by epigenetic mechanisms in breast cancer lines. In the
study by Rahmini et al[202], co-administration of the
HSP90 antagonist 17-allylamino-17-demethoxy-geldan-
amycin (17-AAG) and SAHA induced synergistic induc-
tion of mitochondrial damage, caspase activation (-3 and
-8), and apoptosis in several different human leukaemia
cell lines. These investigators found that co-administra-
tion of 17-AAG with SAHA blocked the SAHA mediated
induction of the cyclin-dependent kinase inhibitor,
p21WAF1/CIP1, and that this novel finding might explain
why the combination treatment was more effective. When
cells were forced to express p21WAF1/CIP1, the combination
treatment was far less effective[202].
Proteins that recognize distorted DNA structures: Tata 
Box Binding Protein and High Mobility Group proteins
In many cases the interaction of small molecules with
DNA results in a distortion in the normal DNA structure.
This distortion may result in the inhibition or induction
of protein binding at or in the vicinity of the perturbation.
The outcomes of the alteration vary and may be more or
less dependent on the primary nucleotide sequence. In
this subsection, TBP and HMG proteins are discussed.
Cis-diamminedichloroplatinum [40] (cisplatin) is a DNA
alkylator that forms predominantly intrastrand crosslinks
by binding to the N7 nitrogen of adjacent guanidine resi-
dues or guanidine-adenine residues. Cisplatin binding
causes a structural distortion in the DNA (bend of 40–
60°, and twist of 25–32°) as revealed by crystallography
and NMR spectroscopy[203]. The cisplatin-distorted DNA
activates binding of a number of nuclear proteins such as
TBP, p53, HMG1, and H1[23,24,204-208]. In the case of
TBP, binding is somewhat sequence dependent, although
the preferred sequence is not the TBP consensus
sequence[208]. It has been suggested that the affinity of
TBP for cisplatin-modified DNA is because the DNA dis-
tortion caused by cisplatin crosslinking is similar to TATA
box DNA structure when bound to TBP[209].
The effects of cisplatin treatment include inhibition of
DNA synthesis and RNA transcription, effects on the cell
cycle, and activation of apoptosis[207]. The binding of
HMG1 to the cisplatin adduct has been shown to block
translesion DNA synthesis in vitro [210]. Studies by He et
al.[211] suggest that the interaction of HMG1 and the
DNA adduct increases the cytotoxic potential of cisplatin.
In these experiments, breast cancer cells were induced to
over express HMG1 by pre-treatment with estrogen and
were shown to be more sensitive to cisplatin than unin-
duced cells. This sensitization could be because DNA rep-
lication is halted either directly or because DNA adducts
are no longer effectively recognized by cellular nucleotide
excision repair machinery[212,213].
While cisplatin has been effective in treating a number of
different cancer types including testicular cancer, ovarian
cancer, head and neck cancer, the onset of resistance has
limited its use[207,214]. In general, the degree of
cytotoxicity of cisplatin is correlated with the formation
and duration of DNA adducts, therefore processes that
interfere with these will contribute to the development of
resistance. The pathways that have been implicated in the
development of resistance to cisplatin include pharmaco-
logic-based mechanisms (reduced drug uptake and
increased drug inactivation) as well as mechanisms that
inhibit apoptotic signalling. Some of these anti-apoptotic
mechanisms include increased repair of the cisplatin-
DNA adducts and/or masking of the DNA damage by cre-
ating unnatural protein binding sites and/or inducing
binding of proteins such as HMG1, and H1
[1,14,203,215]. Additionally, many studies point to the
DNA adduct masking (repair shielding) as a process
strongly involved in potentiating cytotoxicity[212].Cell & Chromosome 2004, 3 http://www.cellandchromosome.com/content/3/1/2
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Chemical Structures 1–8 Figure 2
Chemical Structures 1–8. The chemical structures of chlorambucil, melphalan, cyclophosphamide, streptozotocin, dacar-
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Chemical Structures 9–13 Figure 3
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Chemical Structures 14–18 Figure 4
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Chemical Structures 19–22 Figure 6
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Chemical Structures 23–31 Figure 7
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Conclusions
The nucleus offers a variety of potential targets for anti-
cancer drug design. Historically, most nucleus-specific
agents have been designed to interact with DNA, causing
extensive DNA damage leading to induction of cell death.
The new strategy in drug design is to tailor the drug to the
specific cancer diagnosed in an attempt to provide the
most suitable treatment with the least deleterious side
effects to the patient. The outcomes of this approach
include drugs targeting specific signalling molecules such
as BCR/ABL in the case of Glivec and chronic myeloge-
nous leukemia[216]. In addition to reduced toxicity,
using defined targets in combination therapy may help to
reduce the development of drug resistance. Targeting spe-
cific key molecules in the nuclear environment, such as
chromatin-associated proteins, proteins involved in repli-
cation, recombination, repair, and transcription is
another level at which to disrupt requisite cancer-promot-
ing pathways. The HDAC inhibitors in combination with
the DMNTs shows promise of specifically activating genes
that are important tumour suppressors silenced by hyper-
methylation more effectively than when used as single
agents. Many topoisomerase targeted compounds have
been successfully used in the clinic thus far, and certainly
set the stage for the targeting of other proteins involved in
DNA replication and recombination including some
important helicases and repair proteins. The DNA-associ-
ated HMG proteins are another useful target and set a
precedent for examining other DNA distortion- recogniz-
ing proteins and proteins that bind to specific DNA
regions such as MARs.
Alternatively, as we understand more about genomic
DNA itself, specific sequences and regions, secondary
structures, nucleosome formation and higher-order com-
paction, and interactions with the nuclear matrix and
associated proteins, drugs have been and will continue to
be designed to disrupt these processes specifically. It is
Chemical Structures 32–35 Figure 8
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hoped that this approach will provide the same benefits as
outlined above for targeting the associated proteins, but
may be broader by interfering with multiple processes
that occur at the affected locations.
An exciting area of research being developed is conjuga-
tion of compounds capable of recognizing certain
sequences with compounds that exert another function.
Examples of this are the polyamide-chlorambucil and CBI
conjugates[93,94] that connect highly specific DNA
sequence recognition with DNA alkylation and mostly
work by inhibiting specific gene expression, but this
approach could be extended to facilitate targeting of the
DNMT and HDAC inhibitors, for instance, to specific
tumour suppressor promoters to activate transcription.
Lastly, another important area of research is focused on
taking these small molecules and developing them into
tumour-specific pro-drugs as another means of reducing
deleterious side effects to the patient[217].
Abbreviations used
HPLC high performance liquid chromatography
PCR polymerase chain reaction
bp base pairs
HMG High Mobility Group




NMR nuclear magnetic resonance
FISH fluorescence in situ hybridization
MTBP/TRF2 Membrane Tel binding protein
Tel Telomere
FAS APO-1, CD95, death receptor for FAS ligand
TNF Tumour Necrosis Factor
ATM Ataxia-telangiectasia Mutated
ATR Ataxia-telangiectasia Mutated and RAD3-related
ChK1,2 Checkpoint Kinase
BRCA-1 Breast Cancer gene 1
NBS Nijmegen breakage syndrome
MRE Meiotic recombination
MSH Mut S homologue
MLH Mut L homologue
CDK Cyclin-dependent kinase
Chemical Structures 36–40 Figure 9
Chemical Structures 36–40. The chemical structures of 
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Rb Retinoblastoma
E2F E2 Factor




ELF member of the ETS family of trabscription factors
NFκB Nuclear factor of κ Chain from B cells
MAR Matrix attachment region
FRA Fragile site
c-MYC homologue to the oncogene v-myc isolated from
MC29 myelocytomatosis virus
CBI Cyclopropylbenzindoline
gpt xanthine-guanine phophoribosyl transferase gene
TBP Tata Box Binding Protein
SP1 Specificty Protein
SV40 Simion virus 40
Py-Im pyrrole-imidazole
ETS E-26 avion erthroblastosis virus transformation spe-
cific protein
HIV Human immunodeficiency virus
LSF also known as LBP-1, UBP, CP-2
Py-Im-Chl Py-Im chlorambucil
Et-743 Ecteinascidin 743
NF-Y Nuclear Factor Y
MDR Multi-drug resistance




ERG1 Early Growth Response Factor
SRF Serum Response Factor
ssDB single-strand DNA break
TEP1 also known as PTEN, MMAC1
hTER RNA moiety of telomerase
hTERT Catalytic subunit of telomerase





MBP Methyl Binding Protein
MeCP Methyl Cytosine binding Protein
SWI/SNF global transcriptional activation multi-protein
complex
SAGA Histone acetyltransferase complex (Spt/Ada/Gcn5/
acetylase)
Sir2,3,4 yeast transcriptional silencer proteins
SAHA suberoylanilide hydroxamic acid
p53 Protein 53
BCR/ABL fusion protein resulting from a translocation of
BCR and ABL genes
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